ClinicalTrials.gg
CompletedNCT01711853Updated Jan 13, 2015Results posted

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

A Phase 1 interventional study of Dabigatran Etexilate in Renal Insufficiency, Chronic, sponsored by Boehringer Ingelheim. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-01-13.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.

Enrollment
10th of 10
19 · median 242
Started
2012
the only one that year
Phase 1
2 of 13
none open now
Registered
1st of 13
by date

Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2012, is one of 2 in phase 1, and was the 1st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim as a file.
02

Study summary

The study to be conducted is a prospective, open label trial. It is designed to evaluate the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran etexilate in patients with chronic kidney disease.

03

Conditions studied

  • Renal Insufficiency, Chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 18 years and older
  2. Impaired renal function defined as a stable and/or actual creatinine clearance between 15-30 ml/min over the last 3 months before study participation.
  3. The single use of either aspirin or Vitamin K Antagonists
  4. Provision of .

Exclusion criteria

Exclusion criteria:

  1. Unstable renal function and Creatinin Clearance \<15mL/min
  2. Patients treated with two or more aggregation inhibitors
  3. Use of or indication for therapeutic heparin
  4. Patients with prosthetic heart valves
  5. Haemorrhagic disorder or bleeding diathesis
  6. Platelet count \<100 109/L) at screening or during the last 30 days before screening.
  7. Participation in another drug trial in the last 30 days before screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Dabigatran Etexilate

    patient to receive a capsule containing 75 mg of dabigatran etexilate

    Drug: Dabigatran Etexilate

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax,ss

    Maximum concentration of Dabigatran etexilate in plasma at steady state was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.

    Time frame: -0.5 hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 23.5h, 47.5h, 71.5h, 95.5h, 119.5h, 155.5h, 167.5h, 168.5h, 169h, 170h, 171h, 172h, 174h, 176h, 179.5h, 180h, 192h, 216h, 240h

  2. AUCtau,ss

    Area under the plasma concentration-time curve of the total dabigatran at steady state over a uniform dosing interval tau was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.

    Time frame: -0.5 hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 23.5h, 47.5h, 71.5h, 95.5h, 119.5h, 155.5h, 167.5h, 168.5h, 169h, 170h, 171h, 172h, 174h, 176h, 179.5h, 180h, 192h, 216h, 240h

07

Results

Posted Jan 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneDabigatran 75 mg
Started19
Completed16
Not completed3
Withdrew: Not treated3

Outcome measures

PrimaryCmax,ss

Maximum concentration of Dabigatran etexilate in plasma at steady state was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.

Time frame:
-0.5 hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 23.5h, 47.5h, 71.5h, 95.5h, 119.5h, 155.5h, 167.5h, 168.5h, 169h, 170h, 171h, 172h, 174h, 176h, 179.5h, 180h, 192h, 216h, 240h
Reported as:
Geometric mean · ng/mL
Cmax,ss
ng/mLDabigatran 75 mg
Cmax,ss207 ± 53.9
Statistical analysis
  • Dabigatran 75 mg · ANOVA · p = 0.5186ANOVA model on the logarithmic scale; effects accounting for the following sources of variation: 'gender', 'age group', and 'renal function group'.
  • Dabigatran 75 mg · ANOVA · p = 0.9883ANOVA model on the logarithmic scale; effects accounting for the following sources of variation: 'gender', 'age group', and 'renal function group'.
  • Dabigatran 75 mg · ANOVA · p = 0.7853ANOVA model on the logarithmic scale; effects accounting for the following sources of variation: 'gender', 'age group', and 'renal function group'.
PrimaryAUCtau,ss

Area under the plasma concentration-time curve of the total dabigatran at steady state over a uniform dosing interval tau was measured. The samples for pharmacokinetics had to be taken from 30 min before drug administration up to 11 days after drug administration.

Time frame:
-0.5 hours (h), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 23.5h, 47.5h, 71.5h, 95.5h, 119.5h, 155.5h, 167.5h, 168.5h, 169h, 170h, 171h, 172h, 174h, 176h, 179.5h, 180h, 192h, 216h, 240h
Reported as:
Geometric mean · ng*h/mL
AUCtau,ss
ng*h/mLDabigatran 75 mg
AUCtau,ss2140 ± 51.9
Statistical analysis
  • Dabigatran 75 mg · ANOVA · p = 0.4692ANOVA model on the logarithmic scale; effects accounting for the following sources of variation: 'gender', 'age group', and 'renal function group'.
  • Dabigatran 75 mg · ANOVA · p = 0.9734ANOVA model on the logarithmic scale; effects accounting for the following sources of variation: 'gender', 'age group', and 'renal function group'.
  • Dabigatran 75 mg · ANOVA · p = 0.9201ANOVA model on the logarithmic scale; effects accounting for the following sources of variation: 'gender', 'age group', and 'renal function group'.

Adverse events

Collected over Up to Day 11. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran 75 mg—0/16 (0%)6/16 (37.5%)
Most frequent other events
Most frequent other events
EventDabigatran 75 mg
DiarrhoeaGastrointestinal disorders2/16
Gastrooesophageal reflux diseaseGastrointestinal disorders1/16
NauseaGastrointestinal disorders1/16
VomitingGastrointestinal disorders1/16
Nail injuryInjury, poisoning and procedural complications1/16
WoundInjury, poisoning and procedural complications1/16
ThrombophlebitisVascular disorders1/16

Baseline characteristics

Treated set (TS) which included all patients who had taken at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(years)Dabigatran 75 mg
Mean72.7 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran 75 mg
Female3
Male13
08

Study locations

1 site
  • 1160.166.31001 Boehringer Ingelheim Investigational Site
    Leiden, Netherlands
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2012
First posted
Oct 22, 2012
Start
Oct 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Jan 13, 2015
Last update
Jan 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01711853
Responsible party
Sponsor
First posted
Oct 22, 2012
Start date
Oct 2012
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Jan 13, 2015
Last update
Jan 13, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion